PsyMed Ventures Newsletter

Share this post

Microdosing (Part 3): The path to FDA approval with Diamond Therapeutics and MindMed

psymedventures.substack.com

Microdosing (Part 3): The path to FDA approval with Diamond Therapeutics and MindMed

Business Trip, a podcast about psychedelic entrepreneurship

PsyMed Ventures
Aug 16, 2022
1
Share this post

Microdosing (Part 3): The path to FDA approval with Diamond Therapeutics and MindMed

psymedventures.substack.com

Welcome back to Business Trip, a podcast about psychedelic entrepreneurship! 🍄

This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications.

In this episode, we wanted to understand how companies are designing their FDA clinical trials for microdosing. Most importantly, what will it take to get FDA approval? We chat with the chief medical officers of Diamond Therapeutics and MindMed about their clinical programs. Diamond's program uses synthetic psilocybin and is focused on anxiety disorders. Meanwhile, MindMed is using low doses of LSD to treat adult ADHD. Our guests are Dr. Mike McDonnell (Diamond Therapeutics) and Dr. Dan Karlin (MindMed).

Listen here

In this episode, we discuss:

  • Overview of ADHD, anxiety disorders, and how microdosing may treat them

  • The designs for their FDA clinical trials

  • The decision between using psilocybin vs. LSD

Listen to the episode here, on Spotify or Apple Podcasts.

In case you missed it: In Part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In Part 2, we discussed placebo effect and the results of a self-blinded placebo-controlled study with Balázs Szigeti from the Centre for Psychedelic Research at Imperial College London.

Disclaimer: This is not investment advice and is for information and educational purposes only.


About Us

Business Trip tells the story of the emerging industry of psychedelics. Each episode features a new company in the field, ranging from biotech startups developing novel compounds, to clinics and retreats for healing, to software companies building tools to power the ecosystem. 

Business Trip is produced by Greg Kubin and Matias Serebrinsky — we’re partners at PsyMed Ventures, advocates of the healing powers of psychedelic medicine and see a bright future ahead for the industry.

Thanks for listening,

Matias and Greg

💖 Know someone who would enjoy Business Trip?

Follow us on Twitter & Instagram.

Share this post

Microdosing (Part 3): The path to FDA approval with Diamond Therapeutics and MindMed

psymedventures.substack.com
Comments
TopNewCommunity

No posts

Ready for more?

© 2023 Business Trip
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing